Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REEM H GHALIB

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1558337782
CMS profile
25140
Location
ARLINGTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,495.98

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,102.41 4
Food and Beverage $393.57 10

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REEM H GHALIB

NPI 1558337782 · CMS profile ID 25140

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ARLINGTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558337782?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REEM H GHALIB, NPI 1558337782, CMS profile ID 25140. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558337782?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). REEM H GHALIB, NPI 1558337782, CMS profile ID 25140. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558337782?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
REEM H GHALIB, NPI 1558337782, CMS profile ID 25140, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1558337782?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $1,495.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $26.8311/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135362344 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.2911/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153747958 CMS
Fresenius Kabi USA, LLC $26.7607/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146958919 CMS
Janssen Biotech, Inc. $17.5907/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078682922 CMS
Merck Sharp & Dohme LLC $64.9905/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141764613 CMS
Merck Sharp & Dohme LLC $27.7405/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141888605 CMS
Merck Sharp & Dohme LLC $39.9805/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141889486 CMS
Merck Sharp & Dohme LLC $180.9305/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141764605 CMS
Merck Sharp & Dohme LLC $280.6205/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141764611 CMS
Merck Sharp & Dohme LLC $115.6805/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141764615 CMS
Merck Sharp & Dohme LLC $98.7305/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141764749 CMS
Merck Sharp & Dohme LLC $542.1305/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141764767 CMS
ABBVIE INC. $15.6905/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103791799 CMS
Lilly USA, LLC $34.0201/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135381711 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $21.29 1
PY2020 $20.65 1
PY2021 $46.95 3
PY2024 $1,495.98 14
PY2025 $3,750.18 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $336,955.82 118
PY2024 Principal investigator $109,074.86 23
PY2023 Principal investigator $199,670.85 30
PY2022 Principal investigator $179,855.97 19
PY2021 Principal investigator $397,738.75 463
PY2020 Principal investigator $682,337.38 146
PY2019 Principal investigator $775,822.80 163

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

463 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $11,202.38 12/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
POCC in NASH No dispute reported 06/30/2026 828345769
Principal investigator 1 Merck Sharp & Dohme Corporation $194.15 12/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B MK-5172 MK-3682 MK-8408 Fixed Dose Combination FDC in Subjects with Chronic HCV GT1 or GT3 Infection who have failed a Direct Acting Antiviral Regimen No dispute reported 06/30/2026 848750887
Principal investigator 1 Merck Sharp & Dohme Corporation $38,691.76 12/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals with Pre-cirrhotic Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 848751193
Principal investigator 1 Merck Sharp & Dohme Corporation $212.41 12/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals with Pre-cirrhotic Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 848751195
Principal investigator 1 Merck Sharp & Dohme Corporation $25,735.02 12/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide MK-6024 in Individuals With Nonalcoholic Fatty Liver Disease No dispute reported 06/30/2026 848752141
Principal investigator 1 Merck Sharp & Dohme Corporation $2,180.69 12/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide MK-6024 in Individuals With Nonalcoholic Fatty Liver Disease No dispute reported 06/30/2026 848752143
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,446.73 12/22/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836202495
Principal investigator 1 Novo Nordisk AS $18,758.79 12/22/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626031
Principal investigator 1 Novo Nordisk AS $2,000.00 12/22/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897125
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,626.50 12/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836201611
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $50.14 12/01/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
POCC in NASH No dispute reported 06/30/2026 828388583
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.50 12/01/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
POCC in NASH No dispute reported 06/30/2026 828388585
Principal investigator 1 Novo Nordisk AS $10,606.72 11/22/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838477
Principal investigator 1 Gilead Sciences, Inc. $10,396.00 11/17/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803526237
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,904.76 11/17/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836200585
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773419
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773421
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773423
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773425
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773427
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773429
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773431
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773433
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773435
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773473
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773475
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773477
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773479
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773481
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773483
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773485
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773487
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773489
Principal investigator 1 Novo Nordisk AS $150.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773491
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773493
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773495
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773497
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773499
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773501
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773503
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773505
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773507
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773509
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773547
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773549
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773551
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773553
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773555
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773557
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773559
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773561
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773563
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773565
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773567
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773569
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773571
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773573
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773575
Principal investigator 1 Novo Nordisk AS $100.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773577
Principal investigator 1 Novo Nordisk AS $100.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773579
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773581
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773763
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773765
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773767
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773769
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773771
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773773
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773775
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773777
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773779
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773781
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773783
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773785
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773787
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773789
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773791
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773793
Principal investigator 1 Novo Nordisk AS $88.05 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773795
Principal investigator 1 Novo Nordisk AS $88.05 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811773797
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803191
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803193
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803195
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803197
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803199
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803201
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803203
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803205
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803207
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803209
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803211
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803213
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803215
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803217
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803219
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803221
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803223
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803225
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803227
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803229
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803231
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803233
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803235
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803237
Principal investigator 1 Novo Nordisk AS $100.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803239
Principal investigator 1 Novo Nordisk AS $100.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803241
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803243
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803245
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803247
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803249
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803251
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803253
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803255
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803257
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803259
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803261
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803263
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803265
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803267
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803269
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803271
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803273
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803275
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803277
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803279
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803281
Principal investigator 1 Novo Nordisk AS $88.05 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811803283
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811805965
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897037
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897039
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897041
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897043
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897045
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897047
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897049
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897051
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897053
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897055
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897057
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897059
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897061
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897063
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897065
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897067
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897069
Principal investigator 1 Novo Nordisk AS $88.05 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897071
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897073
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897075
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897077
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897079
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897081
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897083
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897085
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897087
Principal investigator 1 Novo Nordisk AS $100.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897089
Principal investigator 1 Novo Nordisk AS $100.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897091
Principal investigator 1 Novo Nordisk AS $100.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897093
Principal investigator 1 Novo Nordisk AS $100.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897095
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897097
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897099
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897101
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897103
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897105
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897107
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897109
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897111
Principal investigator 1 Novo Nordisk AS $100.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897113
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897115
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897117
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897119
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897121
Principal investigator 1 Novo Nordisk AS $88.05 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897123
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811897853
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908609
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908611
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908613
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908615
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908617
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908619
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908621
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908623
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908625
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908627
Principal investigator 1 Novo Nordisk AS $150.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908629
Principal investigator 1 Novo Nordisk AS $150.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908631
Principal investigator 1 Novo Nordisk AS $150.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908633
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908635
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908637
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908639
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908641
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908643
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908645
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908647
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908649
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908651
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908653
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908655
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908657
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908659
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908661
Principal investigator 1 Novo Nordisk AS $100.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908663
Principal investigator 1 Novo Nordisk AS $100.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908665
Principal investigator 1 Novo Nordisk AS $100.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908667
Principal investigator 1 Novo Nordisk AS $100.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908669
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908671
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908673
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908675
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908677
Principal investigator 1 Novo Nordisk AS $28.45 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908679
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908681
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908683
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908685
Principal investigator 1 Novo Nordisk AS $16.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908687
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908689
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908691
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908693
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908695
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908697
Principal investigator 1 Novo Nordisk AS $7.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908699
Principal investigator 1 Novo Nordisk AS $100.00 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908701
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908703
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908705
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908707
Principal investigator 1 Novo Nordisk AS $14.25 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908709
Principal investigator 1 Novo Nordisk AS $88.05 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908711
Principal investigator 1 Novo Nordisk AS $88.05 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908713
Principal investigator 1 Novo Nordisk AS $88.05 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811908715
Principal investigator 1 Novo Nordisk AS $22.50 11/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9500-4656 No dispute reported 06/30/2026 811909363
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $51.14 11/01/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
POCC in NASH No dispute reported 06/30/2026 828388571
Principal investigator 1 Gilead Sciences, Inc. $3,000.00 11/01/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects with Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 803526235
Principal investigator 1 Novo Nordisk AS $41,145.21 10/27/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811311361
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $662.18 10/26/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
POCC in NASH No dispute reported 06/30/2026 828388591
Principal investigator 1 Gilead Sciences, Inc. $192.00 10/20/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803526233
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,752.66 10/20/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836199175
Principal investigator 1 Novo Nordisk AS $70.44 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310953
Principal investigator 1 Novo Nordisk AS $70.44 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310963
Principal investigator 1 Novo Nordisk AS $1.30 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310973
Principal investigator 1 Novo Nordisk AS $26.16 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811311333
Principal investigator 1 Novo Nordisk AS $26.16 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811311343
Principal investigator 1 Novo Nordisk AS $70.44 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625935
Principal investigator 1 Novo Nordisk AS $70.44 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625945
Principal investigator 1 Novo Nordisk AS $70.44 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625955
Principal investigator 1 Novo Nordisk AS $70.44 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625971
Principal investigator 1 Novo Nordisk AS $70.44 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625981
Principal investigator 1 Novo Nordisk AS $1.30 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625991
Principal investigator 1 Novo Nordisk AS $26.16 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626001
Principal investigator 1 Novo Nordisk AS $26.16 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626011
Principal investigator 1 Novo Nordisk AS $26.16 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626021
Principal investigator 1 Novo Nordisk AS $1.30 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838461
Principal investigator 1 Novo Nordisk AS $1.30 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838473
Principal investigator 1 Novo Nordisk AS $26.16 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838475
Principal investigator 1 Novo Nordisk AS $70.44 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865317
Principal investigator 1 Novo Nordisk AS $26.16 10/07/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865319
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $51.22 10/01/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
POCC in NASH No dispute reported 06/30/2026 828388579
Principal investigator 1 Novo Nordisk AS $7,640.19 09/27/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811311351
Principal investigator 1 Novo Nordisk AS $7,369.30 09/27/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 811352507
Principal investigator 1 Novo Nordisk AS $7,369.30 09/27/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 811652047
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,628.99 09/22/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836198015
Principal investigator 1 Boehringer Ingelheim International GmbH $27,264.57 09/01/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 828345767
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $52.26 09/01/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 828388563
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $44.40 09/01/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 828388565
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $483.00 09/01/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 828388567
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,725.60 08/25/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836197777
Principal investigator 1 Gilead Sciences, Inc. $1,160.00 08/23/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803526231
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,752.66 08/18/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836197615
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,245.90 08/04/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836197505
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $52.52 08/01/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 828388547
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $114.00 07/27/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 828388569
Principal investigator 1 Novo Nordisk AS $900.00 07/26/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 811868123
Principal investigator 1 Gilead Sciences, Inc. $1,530.00 07/21/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B No dispute reported 06/30/2026 803516511
Principal investigator 1 Gilead Sciences, Inc. $2,270.00 07/21/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803526229
Principal investigator 1 Intercept Pharmaceuticals, Inc. $4,850.33 07/21/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836197207
Principal investigator 1 Allergan, Inc. $5,500.00 07/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789018981
Principal investigator 1 Allergan, Inc. $400.00 07/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789018983
Principal investigator 1 Allergan, Inc. $1,000.00 07/15/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789018985
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $52.46 07/01/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
POCC in NASH No dispute reported 06/30/2026 828388577
Principal investigator 1 Novo Nordisk AS $2,000.00 06/30/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865173
Principal investigator 1 Novo Nordisk AS $75.00 06/25/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310983
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $640.05 06/24/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 828388561
Principal investigator 1 Allergan, Inc. $5,668.30 06/23/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789018979
Principal investigator 1 Gilead Sciences, Inc. $7,027.00 06/23/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803526227
Principal investigator 1 Intercept Pharmaceuticals, Inc. $5,725.60 06/23/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836196803
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,642.40 06/23/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836196805
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $486.57 06/18/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 828388551
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $69.00 06/06/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 828388549
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $14.80 06/06/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 828388553
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $24.60 06/06/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 828388555
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $133.00 06/06/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 828388557
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $54.13 06/01/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
POCC in NASH No dispute reported 06/30/2026 828388581
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $756.09 05/26/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 828388559
Principal investigator 1 Intercept Pharmaceuticals, Inc. $845.00 05/26/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836196451
Principal investigator 1 Novo Nordisk AS $2,298.60 05/26/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 811840191
Principal investigator 1 Gilead Sciences, Inc. $4,449.00 05/19/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803526225
Principal investigator 1 Intercept Pharmaceuticals, Inc. $13,158.49 05/19/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836196239
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $125.00 05/17/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
POCC in NASH No dispute reported 06/30/2026 828388573
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $25.00 05/17/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
POCC in NASH No dispute reported 06/30/2026 828388587
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $125.00 05/17/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
POCC in NASH No dispute reported 06/30/2026 828388589
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $73.30 05/05/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 840492041
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $53.21 05/01/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
POCC in NASH No dispute reported 06/30/2026 828388575
Principal investigator 1 Gilead Sciences, Inc. $1,136.00 04/26/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803526223
Principal investigator 1 Novo Nordisk AS $900.00 04/23/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 811652065
Principal investigator 1 Novo Nordisk AS $8,250.00 04/23/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 811871829
Principal investigator 1 Novo Nordisk AS $9,000.00 04/23/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 811871831
Principal investigator 1 Intercept Pharmaceuticals, Inc. $5,463.35 04/21/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836195841
Principal investigator 1 Alnylam Pharmaceuticals Inc. $75.00 04/15/2021 Non-covered Recipient Entity
Texas Clinical Research Institute, LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828418749
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/15/2021 Non-covered Recipient Entity
Texas Clinical Research Institute, LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828418751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $35.00 04/15/2021 Non-covered Recipient Entity
Texas Clinical Research Institute, LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828418753
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 04/15/2021 Non-covered Recipient Entity
Texas Clinical Research Institute, LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828418755
Principal investigator 1 PFIZER INC. $6,299.15 04/09/2021 Non-covered Recipient Entity
Texas Clinical Research Institute LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF06865571 DGAT2I ALONE AND WHEN COADMINISTERED WITH PF05221304 ACCI IN ADULT PARTICIPANTS WITH BIOPSYCONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3 No dispute reported 06/30/2026 832904807
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $51.89 04/01/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 828388543
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307155
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307165
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307175
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307185
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307195
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307205
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307213
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307223
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307233
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307241
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307251
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307259
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307269
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307279
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307289
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307297
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811307305
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310809
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310817
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310827
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310837
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310847
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310857
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310867
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310875
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310885
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310895
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310905
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310913
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310923
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310933
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811310943
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811311371
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811311381
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811311387
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625765
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625775
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625785
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625795
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625805
Principal investigator 1 Novo Nordisk AS $3.12 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625815
Principal investigator 1 Novo Nordisk AS $3.12 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625825
Principal investigator 1 Novo Nordisk AS $20.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625835
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625845
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625855
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625865
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625875
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625885
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625895
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625905
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625915
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625925
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626041
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626221
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626229
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626239
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626249
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626259
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626269
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626279
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626289
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626297
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626305
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626315
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811626325
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811648867
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838413
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838415
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838417
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838419
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838421
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838423
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838425
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838427
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838429
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838431
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838433
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838435
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838437
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838439
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838441
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838443
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838445
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838447
Principal investigator 1 Novo Nordisk AS $3.12 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838449
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838451
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838453
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838455
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838457
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838459
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838463
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838465
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838467
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838469
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838479
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838481
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838483
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838485
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838487
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838489
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838491
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838493
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838495
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838497
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838499
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838501
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838503
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811838505
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865175
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865177
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865179
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865181
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865285
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865287
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865289
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865291
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865293
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865295
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865297
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865299
Principal investigator 1 Novo Nordisk AS $30.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865301
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865303
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865305
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865307
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865309
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865311
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865313
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865315
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865321
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865391
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865393
Principal investigator 1 Novo Nordisk AS $2.65 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865395
Principal investigator 1 Novo Nordisk AS $4.50 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865397
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865399
Principal investigator 1 Novo Nordisk AS $3.25 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865401
Principal investigator 1 Novo Nordisk AS $18.00 03/31/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811865403
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $10.00 03/25/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 828388545
Principal investigator 1 Novo Nordisk AS $1,035.00 03/25/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4553 No dispute reported 06/30/2026 811625963
Principal investigator 1 Intercept Pharmaceuticals, Inc. $4,995.90 03/24/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836195459
Principal investigator 1 Novo Nordisk AS $2,274.30 03/24/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE, LLC
NN9931-4492 No dispute reported 06/30/2026 811352497
Principal investigator 1 Allergan, Inc. $1,439.25 03/17/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789018977
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,880.60 03/17/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836195231
Principal investigator 1 Celgene Corporation $9,223.40 03/10/2021 Non-covered Recipient Entity
Texas Clinical Research Institute, Llc
A Phase 2, Randomized, Double-Blind, Placebo-Contr No dispute reported 06/30/2026 807116141
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,380.60 02/24/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836194919
Principal investigator 1 Allergan, Inc. $1,439.25 02/19/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789018975
Principal investigator 1 Gilead Sciences, Inc. $1,725.00 02/17/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B No dispute reported 06/30/2026 803516509
Principal investigator 1 Gilead Sciences, Inc. $3,000.00 02/17/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 803526221
Principal investigator 1 Intercept Pharmaceuticals, Inc. $876.33 02/17/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836194671
Principal investigator 1 Intercept Pharmaceuticals, Inc. $3,000.00 02/10/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836194607
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,245.90 01/26/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 836194273
Principal investigator 1 Intercept Pharmaceuticals, Inc. $6,141.08 01/26/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 836194275
Principal investigator 1 Gilead Sciences, Inc. $1,374.00 01/20/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 803516507
Principal investigator 1 Gilead Sciences, Inc. $1,160.00 01/20/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803526219
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,319.92 01/01/2021 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS EFFICACY, SAFETY, AND TOLERABILITY OF ORAL TROPIFEXOR (LJN452) & LICOGLIFLOZIN (LIK066) COMBINATION THERAPY, COMPARED TO EACH MONOTHERAPY, FOR TREATMENT OF ADULT PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND LIVER FIBROSIS No dispute reported 06/30/2026 800645869